Pharmaceuticals and MedTech Working Group

Published on 21 August 2014


mr dono widiatmoko


Head of Pharmaceutical and Medical Technology Working Group


Mr. Dono Widiatmoko

Country Government Affairs, Market Access and Communication Head

Novartis Indonesia



anne maria


Deputy Head of Pharmaceutical and Medical Technology Working Group


Ms. Anne Maria Naiborhu

Head of Legal and Compliance,

Actavis Indonesia, PT



mr harimurti listianto


Deputy Head of Pharmaceutical and Medical Technology Working Group


Mr. Harimurti Listianto

Head of Oncology Policy and Market Access,

B. Braun Medical Indonesia



banner pharmaceutical


The Pharmaceutical Working Group was formed in 2008 and has 18 member companies representing various aspects of the pharmaceutical industry. The Head of the Pharmaceutical Working Group is Ms. Hanum Yahya, Sanofi. The Working Group discusses the Negative Investment List, the Industry Law, the Draft Law on Halal Product Guarantee, Indonesian National Standards (SNI), Marketing Practices, the Draft Law on Pharmaceutical Supply, Medical Devices, and Household Health Supply.


Currently 30% of the pharmaceutical manufacturers in Indonesia are foreign companies. In a regional comparison this level is remarkably low indicating that there actually should be room for further development of the sector through foreign investment. Due to the prevailing regulatory framework however, Indonesia has seen no or very limited foreign investment in the sector since 2007. The considerable number of significant, restrictive laws and regulations that the pharmaceutical industry is subject to is hampering the development of the sector. The lifting of these regulations is the main work of the Chemicals & Pharmaceuticals working group. The issues include: Negative List; Decree 1010; threat of price control, draft of Pharmaceuticals and Medical Devises law. The business environment for the sector has not improved during the last couple of years.

For the chemicals side the regulatory issues are not as sufficient. The main concerns are related to import tariffs, and other import related issues such as change in HS codes. Group members have also participated in the Import – Export procedures working group, especially companies with issues related to imports of chemicals and registration of pharmaceuticals.


To download EuroCham's Working Group Brochure, please click here.



 bnp paribas platinum member website

Gold Members